If you have been reading about prothymosin alpha and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-08. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
The activity of this peptide is generally described as immunomodulatory rather than directly antimicrobial. Experimental work links it to signaling through certain Toll-like receptors on dendritic cells and to downstream maturation of antigen-presenting cells. Reported effects include expansion of T cell subsets, shifts in cytokine profiles, and increased natural killer cell activity. These observations come largely from cell culture and animal models, and the precise receptor-level events in humans remain incompletely characterized.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Acetylated peptide | N-terminal acetyl group blocks aminopeptidase attack |
| Residue count | 28 amino acids | Matches the N-terminus of prothymosin alpha |
| Molecular mass | About 3,108 Da | Value for the free, unmodified peptide |
| Isoelectric point | Approximately 4.2 | Acidic; net negative charge at neutral pH |
| Encoding gene | PTMA | Human gene for the precursor protein |
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
== Drying of porous silicon == Porous silicon is systematically prone to presence of cracks when the water is evaporated. The cracks are particularly evident in thick or highly porous silicon layers. The origin of the cracks has been attributed to the large capillary stress due to the minute size of the pores. In particular, it has been known that cracks will appear for porous silicon samples with thickness larger than a certain critical value. Bellet concluded that it was impossible to avoid cracking in thick porous silicon layers under normal evaporating conditions. Hence, several appropriate techniques have been developed to minimize the risk of cracks formed during drying.
In November 2019, he imposed a moratorium on approval of new hydraulic fracturing and steam-injected oil drilling in the state until the permits for those projects could be reviewed by an independent panel of scientists. State agencies resumed issuing new hydraulic fracturing permits in April 2020. In 2021, the Center for Biological Diversity sued the Newsom administration over the continued sale of oil and gas leases, and Consumer Watchdog called for the end of their sale. In April 2021, Newsom committed to ending the sale of gas leases by 2024 and ending oil extraction by 2045. In October 2021, he proposed a 3,200-foot (980 m) buffer between new fossil fuel extraction sites and densely populated areas. In 2022, gas prices in California exceeded $6 per gallon. Newsom attributed this to corporate greed and price gouging by oil companies. He proposed a windfall profits tax and penalty for oil companies in September 2022. On March 28, 2023, Newsom signed a law that authorizes the California Energy Commission to set "a profit threshold above which companies would be assessed a financial penalty", requires petroleum companies to report additional profit data to state regulators, and creates a new oversight division of the California Energy Commission to investigate price gouging in the gasoline industry. In June 2025, Newsom signed California Assembly Bill 130 (2025) into law. In October 2025, Newsom vetoed Senate Bill 682 which sought to limit forever chemicals and Assembly Bill 93 which sought to require data centers to report their water use.
=== PIP1 and PIP2 === The 3-D structures of the open and closed forms of plant aquaporins, PIP1 and PIP2, have been solved (PDB: 4JC6). In the closed conformation, loop D caps the channel from the cytoplasm and thereby occludes the pore. In the open conformation, loop D is displaced up to 16 Å, and this movement opens a hydrophobic gate blocking the channel entrance from the cytoplasm. These results reveal a molecular gating mechanism which appears conserved throughout all plant plasma membrane aquaporins. In plants it regulates water intake/export in response to water availability and cytoplasmic pH during anoxia.
Using a long capillary tube, and including potassium chloride aerosols in the helium gas, the mendelevium atoms can be transported over tens of meters to be chemically analysed and have their quantity determined. The mendelevium can then be separated from the foil material and other fission products by applying acid to the foil and then coprecipitating the mendelevium with lanthanum fluoride, then using a cation-exchange resin column with a 10% ethanol solution saturated with hydrochloric acid, acting as an eluant. However, if the foil is made of gold and thin enough, it is enough to simply dissolve the gold in aqua regia before separating the trivalent actinides from the gold using anion-exchange chromatography, the eluant being 6 M hydrochloric acid. Mendelevium can finally be separated from the other trivalent actinides using selective elution from a cation-exchange resin column, the eluant being ammonia α-HIB.< Using the gas-jet method often renders the first two steps unnecessary. Another possible way to separate the trivalent actinides is via solvent extraction chromatography using bis-(2-ethylhexyl) phosphoric acid (abbreviated as HDEHP) as the stationary organic phase and nitric acid as the mobile aqueous phase. The actinide elution sequence is reversed from that of the cation-exchange resin column, so that the heavier actinides elute later.
== E == E. coli - Ecotin - EIF-W2 protein domain - electrophoresis - electroporation - ELFV dehydrogenase - Ellis–van Creveld syndrome - end labeling - endonuclease - enhancer - enterobacter ribonuclease - enzyme - epitope - ethidium bromide - evolutionary clock - evolutionary footprinting - exon - exonuclease - exosome complex - expression - expression clone - expression vector - extended ELM2 domain -
Sources: en.wikipedia.org
==== Micrococcus lysodeikticus ==== By the measurement of decrease in turbidity of M. lysodeikticus by incubating it with lysozyme, enzymatic activity can be evaluated. 7.5 μL of 0.1 - 1 mg/mL proteins is added to 200 μL of M. lysodeikticus at its optical density (OD) of 1.7 AU, and the mixture is measured at 450 nm periodically for reaction rate calculation. On the contrary to the result from glycol chitosan enzymatic activity, the increasing degree of PEGylation decreased the enzymatic activity. This difference in the trend of the enzymatic activity can be due to PEGylation to free lysine causing steric hindrance and subsequently preventing from forming enzyme-substrate complex in the case of reacting with macromolecule, such as M. lysodeikticus.
As defined by the World Health Organization, air pollution is "contamination of the indoor or outdoor environment by any chemical, physical or biological agent that modifies the natural characteristics of the atmosphere." Polluted air is a mixture of gases and particulate matter whose composition varies with local conditions and sources of contaminants. Concentrations of pollutants, components of particulate matter, and duration and timing of exposure to them, vary with location and time, both regionally and seasonally. Both indoor and outdoor (ambient) air can be polluted. Particulate matter (PM) contains both solids and liquids and is defined in terms of the size of its particles: PM10, diameter <10 μm); PM2.5, < 2.5 μm; or ultrafine, <0.1 μm. Particles PM2.5 or smaller can cross the blood-air barrier in the lungs and the blood-brain barrier in the olfactory system, routes by which they can enter the brain. Particulate matter can be made up of multiple components, some of which are linked to specific types of sources. These include black carbon (combustion processes), ammonium (agriculture), NO2 (traffic‐related pollution), secondary organic aerosols (long‐range transport), and metals such as iron, manganese and lead (e.g. mineral dust). Chemicals in pesticides can be released into air or water, and some can vaporize from water into air, contributing to air pollution. Polycyclic aromatic hydrocarbons (PAHs) are released from incomplete combustion of wood, fossil fuels, and petroleum products, including by smoking and cooking.
=== Classification By Function === Medicines may be classified by their therapeutic function—that is, the role they play in treating or preventing disease. The following table summarizes common categories of medications by their primary use:
Iodoacetamide (IAA) is an organic compound with the chemical formula ICH2CONH2. It is an alkylating agent used for peptide mapping purposes. Its actions are similar to those of iodoacetate. It is commonly used to bind covalently with the thiol group of cysteine so the protein cannot form disulfide bonds. It is also used in ubiquitin studies as an inhibitor of deubiquitinase enzymes (DUBs) because it alkylates the cysteine residues at the DUB active site.
Sources: en.wikipedia.org
Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.
The precursor, prothymosin alpha, is encoded by the PTMA gene in humans. The 28-residue peptide corresponds to the N-terminal segment released from that larger protein.
It is produced as a fragment of prothymosin alpha and is present in many tissues. Circulating concentrations are low, which makes routine measurement difficult.
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.